LeoraHornMDMSc, MHPE

Oncology • Nashville, TN

Assistant Professor, Medicine, Vanderbilt University School of Medicine

Join to view full profile

Dr. Horn is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Horn's full profile

Already have an account?

Office
3601 Tvc
Nashville, TN 37232
Phone+1 615-322-3000

Education & Training

University of Toronto Faculty of MedicineClass of 2002

Certifications & Licensure

TN State Medical License 2009 - 2025

Clinical Trials

A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Start of enrollment: 2009 Jul 16
Completed
Phase 2
NCI 8873: Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCL Start of enrollment: 2011 Jun 01
Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer Start of enrollment: 2012 Jun 01
Completed
Phase 1, Phase 2
Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer Start of enrollment: 2012 Oct 01
Terminated
Early Phase 1
Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer Start of enrollment: 2013 Sep 09
Terminated
Phase 1
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Start of enrollment: 2013 Jun 28
Completed
Phase 3
Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib Start of enrollment: 2014 Jun 01
Withdrawn
Phase 2
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Start of enrollment: 2014 Mar 27
Completed
Phase 3
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer Start of enrollment: 2016 May 11
Completed
Phase 2
Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer Start of enrollment: 2017 Jul 20
Terminated
Phase 1
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors Start of enrollment: 2018 Jul 10
Active, not recruiting
Phase 1, Phase 2
M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2019 Apr 02
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

9288 citations
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott N. Gettinger, David Smith
The New England Journal of Medicine. 2012-06-27
317 citations
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMp...
Stephen V. Liu, Martin Reck, Aaron S. Mansfield, Tony Mok, Arnaud Scherpereel
Journal of Clinical Oncology. 2021-01-13
235 citations
Burnout and Career Satisfaction Among US Oncologists
Tait D. Shanafelt, William J. Gradishar, Michael P. Kosty, Daniel Satele, Helen K. Chew
Journal of Clinical Oncology. 2014-03-01

Journal Articles

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
David S Shames, Leora Horn, Fairooz Kabbinavar, The New England Journal of Medicine

Lectures

Sequencing theTyrosine Kinase Inhibitors
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
Real-world treatment patterns and survival of BRAF V600-mutated metastatic non-small cell lung cancer patients.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

How I Decided to Hold Out for the Best Lung Cancer TreatmentDecember 9th, 2022
Black, Low-Income Patients with Cancer at Highest Risk for Severe COVID-19 ComplicationsAugust 2nd, 2021
Kidney Damage from COVID-19 Linked to Higher Risk of in-Hospital DeathSeptember 22nd, 2020
Join now to see all